Extension usage examples:
Here's how our browser extension sees the article:
High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis | Neurology
Source: n.neurology.org
Article summary:
1. A high-precision plasma β-amyloid 42/40 assay accurately diagnoses brain amyloidosis using amyloid PET or CSF p-tau181/Aβ42 as reference standards.
2. The combination of plasma Aβ42/Aβ40, age, and APOE ε4 status had a very high correspondence with amyloid PET (AUC 0.94, 95% CI 0.90–0.97).
3. Individuals with a negative amyloid PET scan at baseline and a positive plasma Aβ42/Aβ40 (<0.1218) had a 15-fold greater risk of conversion to amyloid PET-positive compared to individuals with a negative plasma Aβ42/Aβ40 (p = 0.01).
Article analysis:
The article is generally reliable and trustworthy in its reporting of the findings from the study conducted by James G. Bollinger et al., which examined whether plasma β-amyloid (Aβ)42/Aβ40, as measured by a high-precision assay, accurately diagnosed brain amyloidosis using amyloid PET or CSF p-tau181/Aβ42 as reference standards. The authors provide detailed information on their methods and results, including the receiver operating characteristic area under the curve (AUC), confidence intervals (CI), and p values for each comparison made in the study. Furthermore, they discuss potential limitations of their study such as the small sample size and lack of longitudinal data, which could have affected their results.
The article does not appear to be biased or one-sided in its reporting; it presents both sides equally and provides evidence for all claims made throughout the text. It also does not contain any promotional content or partiality towards any particular viewpoint or opinion on the topic discussed in the article. Additionally, possible risks associated with using this method are noted throughout the text, such as false positives due to age or APOE ε4 status being included in the analysis when determining brain amyloidosis status from plasma Aβ42/Aβ40 levels.
In conclusion, this article is reliable and trustworthy in its reporting of findings from this study examining whether plasma β-amyloid 42/40 can accurately diagnose brain amyloidosis using reference standards such as amyloid PET scans or CSF p-tau181/Aβ42 levels. The authors provide